ReviewJournal of cellular and molecular medicine
New asthma drugs acting on gene expression.
Review in Journal of cellular and molecular medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 26 citations in OpenAlex.
- Article
- Synthesis and in Vitro Evaluation of a Peptidomimetic Inhibitor Targeting the Src Homology 2 (SH2) Domain of STAT6.ACS medicinal chemistry letters · 2014Article
- How to deal with weak interactions in noncovalent complexes analyzed by electrospray mass spectrometry: cyclopeptidic inhibitors of the nuclear receptor coactivator 1-STAT6.Journal of the American Society for Mass Spectrometry · 2009Article
- A review of antisense therapeutic interventions for molecular biological targets in asthma.Biologics : targets & therapy · 2007Article
- Heterogeneity of transcription factor expression and regulation in human airway epithelial and smooth muscle cells.American journal of physiology. Lung cellular and molecular physiology · 2007Article
- Etiology of exercise-induced asthma: physical stress-induced transcription.Current allergy and asthma reports · 2007Review
- The future of antisense oligonucleotides in the treatment of respiratory diseases.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2006Review
- Review
- Antisense- and RNA interference-based therapeutic strategies in allergy.Journal of cellular and molecular medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New asthma drugs acting on transcription are transcription factor agonists (dissociated steroids, peroxisome proliferator-activated receptor gamma agonists), transcription factor inhibitors (NF-kappaB / AP-1 inhibitors, STAT6 inhibitors), inhibitors of protein kinases acting on transcription factors (p38 MAP kinase inhibitors), and chromatin modifying agents. Pharmacological approach of translation in asthma includes therapeutic ribozymes and antisense oligonucleotides targeting receptors (adenosine A1 receptor, alpha chain of IL-5 receptor, common beta chain of IL-3/IL-5/GM-CSF receptor), cytokines (IL-4, IL-5, SCF), signal transduction molecules (Syk, Lyn), transcription factors (STAT-6, GATA-3). Some of these drugs acting on gene expression have the potential to improve therapeutic benefits compared with traditional drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.